$ICUI

Woolson Daniel sold $982K of ICUI

Woolson Daniel (VP, GM-Infusion Capital) sold 5,417 shares of ICU MEDICAL INC/DE (ICUI) at $181.33 ($0.98M total) on 2026-08-13.

Original reporting
SEC EDGAR · Woolson Daniel
Published Aug 13, 2026, 10:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this filing alone does not change earnings power, valuation, or near-term fundamentals.

02

Market read

A new Form 4 sale provides incremental sentiment information for ICUI, but it is unlikely to be a standalone catalyst.

03

What to watch

The transaction is an open-market sale and the article provides no context on total compensation, prior holdings, or whether other insiders sold/bought around the same time.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-13 after-hours/late session

Background

The article is an SEC Form 4 insider transaction disclosure for ICU Medical, Inc. (ICUI).

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical disclosed an insider open-market sale by VP, GM-Infusion Capital Woolson Daniel of 5,417 shares at $181.33 on 2026-08-13.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader flow and any concurrent company news.

Evidence & confidence

Form 4 insider sales are common and the filing states no pre-arranged 10b5-1 plan, but it still does not provide new operating or guidance information.

Market effects

Minimal sector read-through; this is an issuer-specific insider sale without stated operational drivers.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or personal liquidity needs and may not signal reduced business confidence.

Key entities

  • ICU Medical, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Woolson Daniel

    VP, GM-Infusion Capital who sold 5,417 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.